Heparin has been used extensively as an antithrombotic and anticoagulant for close to 100
years. This anticoagulant activity is attributed mainly to the pentasaccharide sequence …

COVID-19 patients have a high incidence of thrombosis, and thromboembolic complications
are associated with severe COVID-19 and high mortality. COVID-19 disease is associated …

Abstract Background: COVID-19–related acute illness is associated with an increased risk of
venous thromboembolism (VTE). Objective: These evidence-based guidelines from the …

Abstract Coronavirus disease 2019 (COVID-19) has emerged as a pandemic at the end of
2019 and continues to exert an unfavorable worldwide health impact on a large proportion …

Arterial and venous thrombotic events in COVID-19 cause significant morbidity and mortality
among patients. Although international guidelines agree on the need for anticoagulation, it …

Importance Given the high risk of thrombosis and anticoagulation-related bleeding in
patients with hypoxemic COVID-19 pneumonia, identifying the lowest effective dose of …

Abstract Coronavirus disease 2019 (COVID-19) associated coagulopathy is multifactorial
and involves inflammation driven hypercoagulability, endothelial dysfunction, platelet …

Thromboembolic events are frequent and life-threating complications of COVID-19 but are
also observed in patients with sepsis. Disseminated thrombosis can occur despite …

Background COVID-19 progression is associated with an increased risk of arterial and
venous thrombosis. Randomised trials have demonstrated that anticoagulants reduce the …

Background Anticoagulation in hospitalized COVID-19 patients has been associated with
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …